Equities analysts expect Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) to post $2.26 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Tetraphase Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $1.50 million and the highest estimate coming in at $3.28 million. Tetraphase Pharmaceuticals reported sales of $1.09 million during the same quarter last year, which indicates a positive year-over-year growth rate of 107.3%. The company is scheduled to report its next quarterly earnings report on Wednesday, March 14th.

According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year sales of $2.26 million for the current year, with estimates ranging from $6.00 million to $10.41 million. For the next financial year, analysts forecast that the company will report sales of $6.58 million per share, with estimates ranging from $5.00 million to $12.41 million. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that follow Tetraphase Pharmaceuticals.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, meeting the consensus estimate of ($0.63). Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. The firm had revenue of $4.10 million during the quarter, compared to the consensus estimate of $1.59 million. During the same period last year, the business posted ($0.58) EPS. Tetraphase Pharmaceuticals’s quarterly revenue was up 355.6% on a year-over-year basis.

Several equities analysts recently weighed in on TTPH shares. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, October 28th. BMO Capital Markets raised their price objective on Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an “outperform” rating in a research note on Wednesday, October 4th. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Tetraphase Pharmaceuticals in a research note on Tuesday, December 5th. Finally, ValuEngine downgraded Tetraphase Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. Tetraphase Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $15.15.

Tetraphase Pharmaceuticals (TTPH) opened at $6.24 on Thursday. Tetraphase Pharmaceuticals has a one year low of $3.57 and a one year high of $9.93. The firm has a market capitalization of $320.83, a P/E ratio of -2.17 and a beta of 2.51.

In related news, Director L Patrick Gage purchased 3,880 shares of the company’s stock in a transaction on Wednesday, November 29th. The stock was bought at an average price of $6.45 per share, with a total value of $25,026.00. Following the completion of the transaction, the director now owns 38,880 shares of the company’s stock, valued at approximately $250,776. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Jacques Dumas sold 7,167 shares of the firm’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $6.21, for a total value of $44,507.07. The disclosure for this sale can be found here. Company insiders own 5.50% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in TTPH. SG Americas Securities LLC purchased a new position in Tetraphase Pharmaceuticals during the third quarter worth $107,000. Brighton Jones LLC purchased a new position in Tetraphase Pharmaceuticals during the third quarter worth $108,000. AXA purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth $132,000. Virtu KCG Holdings LLC purchased a new position in Tetraphase Pharmaceuticals during the second quarter worth $147,000. Finally, Voya Investment Management LLC increased its position in Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 3,104 shares in the last quarter. 58.15% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect Tetraphase Pharmaceuticals Inc (TTPH) Will Announce Quarterly Sales of $2.26 Million” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/18/zacks-analysts-expect-tetraphase-pharmaceuticals-inc-ttph-will-announce-quarterly-sales-of-2-26-million.html.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Get a free copy of the Zacks research report on Tetraphase Pharmaceuticals (TTPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.